Suppr
超能文献

Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?

作者信息

Gainor Justin F

机构信息

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Cancer Cytopathol. 2017 Aug;125(8):591-593. doi: 10.1002/cncy.21882. Epub 2017 Jun 16.

DOI:10.1002/cncy.21882

PMID:28621887

Abstract

摘要

相似文献

Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?

Cancer Cytopathol. 2017 Aug;125(8):591-593. doi: 10.1002/cncy.21882. Epub 2017 Jun 16.

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

Cancer Cytopathol. 2017 Jul;125(7):521-528. doi: 10.1002/cncy.21873. Epub 2017 May 4.

Programmed death ligand 1 testing: is there one best test?

Clin Adv Hematol Oncol. 2017 Jun;15(6):438-440.

[Quiz: Ready, study, score!].

Ann Pathol. 2017 Feb;37(1):7-10. doi: 10.1016/j.annpat.2016.12.014. Epub 2017 Feb 1.

PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

JAMA Oncol. 2016 Jan;2(1):54-5. doi: 10.1001/jamaoncol.2015.3782.

Programmed cell death ligand 1 as a biomarker in head and neck cancer.

Cancer Cytopathol. 2017 Jul;125(7):529-533. doi: 10.1002/cncy.21872. Epub 2017 May 4.

Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.

Diagn Cytopathol. 2018 May;46(5):378-383. doi: 10.1002/dc.23900. Epub 2018 Feb 24.

[The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):799-803. doi: 10.3760/cma.j.issn.1001-0939.2018.10.010.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer.

Arch Pathol Lab Med. 2019 Jan;143(1):11-12. doi: 10.5858/arpa.2018-0410-ED. Epub 2018 Oct 11.

引用本文的文献

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.

Sci Rep. 2018 Jun 26;8(1):9686. doi: 10.1038/s41598-018-27994-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译